Page 181 - CW E-Magazine (21-11-2023)

Document

The policy aims to align India’s regu- ncing industry sustainability with To address the current deficiencies

latory standards with international affordability for patients. in education and research within the
best practices that balances innova- It seeks to establish mechanisms pharma sector and to guarantee the
tion with safety, reducing compli- that prevent price manipulation and provision of high-quality education
ance burdens, ensuring that pharma arbitrary increases, thus safeguard- and training for a skilled workforce
companies can seamlessly adhere to ing the interests of consumers while capable of meeting the evolving
global standards. This harmonisa- providing a predictable environment demands of the rapidly advancing
tion not only streamlines the R&D for pharma companies to thrive. This pharma industry.
process, but also enhances the credi- approach not only assures citizens Establish courses to produce skilled

bility of Indian pharma products on of affordable healthcare options but human resources for advanced manu-
the global stage. also boosts investor confidence, as facturing and research.
To simplify licensing system to it brings stability to the market. Promote entrepreneurship, encour-
avoid duplication of efforts and to Policy aims to complement National age a culture of start-ups and estab-

ensure better coordination among R&D Policy work on regulatory lishment of incubation funds, and
different regulatory authority – streamlining by supporting process promote industry-academia linkages
CDSCO, DCGI, etc. optimisation, development of tech- where industry can directly take
In order to enhance ease of doing nology based/enabled platform, active role in upskilling of students
research and business and further to regulatory capacity, and legislation. through training and taking lab
balance patient safety with product driven research to market by facili-
innovation, measures such as crea- Regulatory harmonisation, price tating access to mentorships.
tion of a single window clearance regulation, and transparency are not
system for licensing of pharmaceu- just administrative processes, but tools Enhancing policy & programme
ticals co-opting all the stakeholder to ensure that patients have access to interlinkages
departments/organisations such as high-quality medicines and healthcare In the dynamic landscape of health-
CDSCO, DCGI, MeitY, DAHD, services when they need them the most. care, the success of NPP 2023 hinges
etc, enhancing the role of Indian It fosters an ecosystem where Indian not only on its intrinsic elements, but
Standards like BIS and designing a pharma companies can compete on the also on its ability to seamlessly interlink
coherent pricing regulation, will be international stage, not just in terms of with existing policies and programmes.
followed. The policy also supports cost-effectiveness, but also in terms of To maximise its impact, the policy
exploring feasibility of roll-out of a quality, innovation, and ethical prac- acknowledges the importance of synergy
mandatory track & trace mechanism tices. and collaboration across various sec-
for products to ensure that high tors and initiatives. There are several
quality drugs reach patients. Initiate capacity building & develop- Departments and policies that are directly
Create equilibrium between social, ment of skilled manpower and indirectly inter-linked with pharma
economic, & governance aspects The policy aims to develop a skilled ecosystem, contributing to its growth
through facilitative, balanced & and diversified talent pool which is and development. These policies need
progressive policy and regulatory competitive in the global scenario by: to make their instruments interoper-
framework. Invest in training programmes, skill able, to create a set of conducive con-
While ensuring that essential medi- development, and continuous edu- ditions that enable the Indian pharma
cines remain affordable to all, the cation for healthcare professionals, ecosystem.
policy seeks to strike a balance that researchers, and manufacturing per- By enhancing policy and program
encourages fair pricing without sti- sonnel to elevate the pharma sec- interlinkages, NPP 2023 aims to
fling innovation. By monitoring tor’s capabilities. The policy aims synchronise its goals with broader
and regulating drug prices, it aims to upskill faculties in NIPER with national objectives such as uni-
to reduce the financial burden on respect to the evolving landscape of versal healthcare access, innova-
patients while maintaining a condu- pharma med-tech industry to impart tion-driven economic growth, and
cive environment for pharma com- best education to new talent pool of sustainable development. This col-
panies to thrive. incoming students. laborative approach ensures the
Implement a rational and transpa- Create qualifications aligned with pharma sector becomes an integral
rent drug pricing mechanism to en- ‘Skill India’ to train professionals part of the holistic healthcare eco-
sure fair pricing of medicines, bala- across the pharma value chain. system, reinforcing the policy’s

Chemical Weekly November 21, 2023 181

Contents Index to Advertisers Index to Products Advertised